JP2017511324A5 - - Google Patents

Download PDF

Info

Publication number
JP2017511324A5
JP2017511324A5 JP2016559965A JP2016559965A JP2017511324A5 JP 2017511324 A5 JP2017511324 A5 JP 2017511324A5 JP 2016559965 A JP2016559965 A JP 2016559965A JP 2016559965 A JP2016559965 A JP 2016559965A JP 2017511324 A5 JP2017511324 A5 JP 2017511324A5
Authority
JP
Japan
Prior art keywords
adjuvant
composition
immunogenic composition
rts
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016559965A
Other languages
English (en)
Japanese (ja)
Other versions
JP6645982B2 (ja
JP2017511324A (ja
Filing date
Publication date
Priority claimed from GBGB1405921.6A external-priority patent/GB201405921D0/en
Application filed filed Critical
Publication of JP2017511324A publication Critical patent/JP2017511324A/ja
Publication of JP2017511324A5 publication Critical patent/JP2017511324A5/ja
Application granted granted Critical
Publication of JP6645982B2 publication Critical patent/JP6645982B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016559965A 2014-04-02 2015-04-02 免疫応答を誘導するための新規の方法 Active JP6645982B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1405921.6A GB201405921D0 (en) 2014-04-02 2014-04-02 Novel methods for inducing an immune response
GB1405921.6 2014-04-02
PCT/EP2015/057424 WO2015150568A1 (en) 2014-04-02 2015-04-02 Novel methods for inducing an immune response

Publications (3)

Publication Number Publication Date
JP2017511324A JP2017511324A (ja) 2017-04-20
JP2017511324A5 true JP2017511324A5 (enExample) 2018-05-17
JP6645982B2 JP6645982B2 (ja) 2020-02-14

Family

ID=50737873

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016560336A Expired - Fee Related JP6655549B2 (ja) 2014-04-02 2015-04-02 免疫応答を誘導するための新規方法
JP2016559965A Active JP6645982B2 (ja) 2014-04-02 2015-04-02 免疫応答を誘導するための新規の方法

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2016560336A Expired - Fee Related JP6655549B2 (ja) 2014-04-02 2015-04-02 免疫応答を誘導するための新規方法

Country Status (18)

Country Link
US (3) US10688168B2 (enExample)
EP (2) EP3125930B1 (enExample)
JP (2) JP6655549B2 (enExample)
KR (2) KR20160132115A (enExample)
CN (2) CN106456739A (enExample)
AR (1) AR099960A1 (enExample)
AU (1) AU2015239025B2 (enExample)
BE (1) BE1022355B1 (enExample)
BR (2) BR112016022787A2 (enExample)
CA (2) CA2943007C (enExample)
EA (1) EA037405B1 (enExample)
ES (2) ES2961840T3 (enExample)
GB (1) GB201405921D0 (enExample)
IL (1) IL247493B (enExample)
MX (3) MX2016012932A (enExample)
SG (1) SG11201607086QA (enExample)
WO (2) WO2015150567A1 (enExample)
ZA (1) ZA201605955B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
GB201621686D0 (en) 2016-12-20 2017-02-01 Glaxosmithkline Biologicals Sa Novel methods for inducing an immune response
FR3066920A1 (fr) 2017-05-30 2018-12-07 Glaxosmithkline Biologicals S.A. Nouveaux procedes de fabrication d'un adjuvant
WO2019106192A1 (en) 2017-12-01 2019-06-06 Glaxosmithkline Biologicals Sa Saponin purification
CA3142300C (en) 2019-06-05 2025-02-04 Glaxosmithkline Biologicals Sa SAPONIN PURIFICATION
CN113125756B (zh) * 2020-07-15 2022-10-25 南京岚煜生物科技有限公司 抗体标准品赋值和抗原中和当量确定的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US152200A (en) * 1874-06-16 Improvement in garters
US1002607A (en) * 1905-08-28 1911-09-05 John Willard Taylor Paper pulley.
UA56132C2 (uk) * 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
EP1569515A4 (en) 2002-10-23 2006-04-26 Glaxosmithkline Biolog Sa MALARIA vaccine method
EA016648B1 (ru) 2004-10-14 2012-06-29 Круселл Холланд Б.В. Применение дефектного по репликации рекомбинантного аденовируса, содержащего гетерологичную нуклеиновую кислоту, кодирующую антиген cs возбудителя малярии, и белкового антигена, содержащего белок cs или его фрагмент, для лечения или профилактики малярии
PL2457926T3 (pl) * 2005-04-29 2015-03-31 Glaxosmithkline Biologicals Sa Nowy sposób profilaktyki lub leczenia zakażenia m. tuberculosis
TWI457133B (zh) 2005-12-13 2014-10-21 Glaxosmithkline Biolog Sa 新穎組合物
EP2368568A1 (en) * 2006-11-01 2011-09-28 Immport Therapeutics, INC. Compositions and methods for immunodominant antigens
HUE031411T2 (en) * 2007-03-02 2017-07-28 Glaxosmithkline Biologicals Sa New Methods and Preparations
PE20090146A1 (es) * 2007-04-20 2009-03-23 Glaxosmithkline Biolog Sa Composicion inmunogenica contra el virus influenza
WO2010010179A1 (en) * 2008-07-25 2010-01-28 Glaxosmithkline Biologicals S.A. The tuberculosis rv2386c protein, compositions and uses thereof
UA107330C2 (uk) * 2008-07-25 2014-12-25 Глаксосмітклайн Байолоджікалз С.А. Туберкульозний білок rv3616c та його застосування
EP2315597B1 (en) * 2008-07-25 2017-08-23 GlaxoSmithKline Biologicals S.A. Novel compositions and methods
PL2528621T3 (pl) * 2010-01-27 2017-07-31 Glaxosmithkline Biologicals S.A. Zmodyfikowane antygeny gruźlicy
HUE028452T2 (en) * 2010-12-14 2016-12-28 Glaxosmithkline Biologicals Sa Mycobacterium antigenic preparations
US20170056345A1 (en) * 2014-02-18 2017-03-02 Stc.Unm Booster drug therapy for mycobacterium infections
GB201405921D0 (en) * 2014-04-02 2014-05-14 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response
JP2017513860A (ja) * 2014-04-24 2017-06-01 スタテンス セールム インスティトゥート 新規結核菌(m.tuberculosis)ワクチン
GB201513176D0 (en) * 2015-07-27 2015-09-09 Glaxosmithkline Biolog Sa Novel methods for inducing an immune response

Similar Documents

Publication Publication Date Title
JP2017511324A5 (enExample)
Weeratna et al. CpG DNA induces stronger immune responses with less toxicity than other adjuvants
Garçon et al. Development and evaluation of AS03, an Adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion
EP3089754B1 (en) Single vial vaccine formulations
WO2006060710A3 (en) Vaccine formulations for intradermal delivery comprising adjuvants and antigenic agents
JP2017511327A5 (enExample)
TW200722101A (en) Novel composition
HRP20230359T1 (hr) Imunogeni pripravak
HUE031740T2 (en) A vaccine composition comprising a synthetic adjuvant
Rosas et al. Remarkably high antibody levels and protection against P. falciparum malaria in Aotus monkeys after a single immunisation of SPf66 encapsulated in PLGA microspheres
Lowell et al. Back to the future: immunization with M-001 prior to trivalent influenza vaccine in 2011/12 enhanced protective immune responses against 2014/15 epidemic strain
US11951161B2 (en) Methods for inducing an immune response
IL276661B2 (en) Immunogenic preparation containing staphylococcal antigens
JP2015520196A5 (enExample)
JP2018532782A5 (enExample)
WO2005074460A3 (en) Methods of enhancing immune response in the intradermal compartment and compounds useful in the methods
Mishra et al. Adjuvant effect of aqueous extract of Rhodiola imbricata rhizome on the immune responses to tetanus toxoid and ovalbumin in rats
Precioso et al. A phase I randomized, double-blind, controlled trial of 2009 influenza A (H1N1) inactivated monovalent vaccines with different adjuvant systems
Al Saleh et al. MicroCrystalline Tyrosine-adsorbed immunotherapy
Sisteré-Oró et al. Influenza NG-34 T cell conserved epitope adjuvanted with CAF01 as a possible influenza vaccine candidate
EP4421174A3 (en) Adjuvant comprising a glycoarchaeol and an immunostimulant
WO2022076723A8 (en) Imdq-peg-chol adjuvant and uses thereof
WO2018206776A1 (en) Dried composition
Kanchan et al. Role of alum in improving the immunogenicity of biodegradable polymer particle entrapped antigens
WO2021101187A3 (ko) 바바킨을 포함하는 신규 백신용 면역보조제 조성물